Skip to main content

Cyteir Therapeutics, Inc.

CYTDelisted Mar 18, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001662244

Cyteir Therapeutics, Inc. was delisted on Mar 18, 2024; its insiders filed their last Form 4 on Mar 25, 2024; 38 institutions reported holding it in 13F filings for Q4 2023, worth $38.9M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Cyteir Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Cyteir Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Cyteir Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Leonard Braden Michael10% Owner3,654,053IndirectMar 25, 20240
Renschler Markus MDPresident and CEO1,103,661Mar 5, 20240
Gaiero David GChief Financial Officer102,391Mar 5, 20240
George JeanDirector14,150Feb 16, 20240
Sands Stephen H.Director12,129Feb 14, 20240
Thero John FDirector22,828Feb 12, 20240
Zakrzewski Joseph SDirector227,439Feb 8, 20240
Novo Holdings A/S10% Owner3,522,136Jul 20, 20230
Molineaux SusanDirector–Feb 7, 20230
Veness Adam MGeneral Counsel–Feb 7, 20230
Humphrey JeffreyDirector–Feb 7, 20230
Bracken RacquelDirector–Feb 7, 20230
Romberger TimothyDirector–Feb 7, 20230
Gengos AndrewChief Business Officer–Feb 24, 20220
Secrist John PaulChief Scientific Officer–Feb 24, 20220
Naesens JanwillemDirector–Feb 24, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 25, 2024 (view filing)Mar 205 daysLateLeonard Braden Michael10% OwnerPPurchaseCommon Stock, par value $0.001 per share+170.6K$2.95+$503.2K+4.9%3.65M after
Mar 19, 2024 (view filing)Mar 181 dayLeonard Braden Michael10% OwnerPPurchaseCommon Stock, par value $0.001 per share+113.8K$3.01+$342.5K+3.4%3.48M after
Jul 20, 2023 (view filing)Jul 19-201 dayNovo Holdings A/S10% OwnerSSale−101.9K$2.75−$280.2K−2.8%3.52M after2 lots
Jul 18, 2023 (view filing)Jul 14-184 daysNovo Holdings A/S10% OwnerSSale−38.6K$2.75−$106.1K−1.1%3.62M after3 lots
Jul 3, 2023 (view filing)Jun 303 daysNovo Holdings A/S10% OwnerSSale−200.9K$2.63−$528.5K−5.2%3.66M after
Jun 28, 2023 (view filing)Jun 26-272 daysNovo Holdings A/S10% OwnerSSale−40.4K$1.77−$71.7K−1.0%3.86M after2 lots
Jun 23, 2023 (view filing)Jun 21-232 daysNovo Holdings A/S10% OwnerSSale−13.3K$1.94−$25.8K−0.3%3.90M after3 lots
Jun 20, 2023 (view filing)Jun 15-205 daysNovo Holdings A/S10% OwnerSSale−16.7K$2.03−$34.0K−0.4%3.92M after3 lots
Jun 14, 2023 (view filing)Jun 12-142 daysNovo Holdings A/S10% OwnerSSale−6.40K$2.10−$13.4K−0.2%3.93M after3 lots
Dec 8, 2022 (view filing)Dec 71 dayZakrzewski Joseph SDirectorPPurchase+21.2K$1.30+$27.6K+15.9%154.6K afterFrom original
Jul 22, 2022 (view filing)Jul 202 daysNovo Holdings A/S10% OwnerSSale−900.0K$3.00−$2.70M−18.6%3.94M after
May 16, 2022 (view filing)May 124 daysZakrzewski Joseph SDirectorPPurchase+743$1.61+$1.20K+0.6%133.4K after
May 12, 2022 (view filing)May 102 daysThero John FDirectorPPurchase+10.0K$2.00+$20.0KNew position10.0K after
May 12, 2022 (view filing)May 10-112 daysZakrzewski Joseph SDirectorPPurchase+50.4K$1.89+$95.1K+61.3%132.7K after2 lots
Dec 28, 2021 (view filing)Dec 23-285 daysZakrzewski Joseph SDirectorPPurchase+1.10K$9.91+$10.9K+1.4%82.3K after4 lots
Dec 21, 2021 (view filing)Dec 174 daysZakrzewski Joseph SDirectorPPurchase+200$9.88+$1.98K+0.2%81.2K after
Dec 15, 2021 (view filing)Dec 15Same dayZakrzewski Joseph SDirectorPPurchase+3.70K$10.77+$39.8K+4.8%81.0K after2 lots